Daejeon, South Korea

Sae-Bom Yoon


 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Sae-Bom Yoon

Introduction

Sae-Bom Yoon is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target autoimmune diseases and tumors. His work exemplifies the intersection of chemistry and medicine, showcasing the potential of innovative solutions in healthcare.

Latest Patents

Sae-Bom Yoon holds a patent for a tricyclic compound as an IRAK4 inhibitor. This invention relates to a pharmaceutical composition designed for the prevention or treatment of autoimmune diseases or tumors. The active ingredient in this composition is a tricyclic compound, which is represented by a specific chemical formula. Additionally, the patent includes a health food composition aimed at preventing or alleviating these medical conditions.

Career Highlights

Sae-Bom Yoon is affiliated with the Korea Research Institute of Chemical Technology, where he conducts research and development in chemical technology. His work has led to advancements in therapeutic options for patients suffering from challenging health conditions. His dedication to innovation in this field is evident through his patent and ongoing research efforts.

Collaborations

Sae-Bom Yoon collaborates with esteemed colleagues, including Heeyeong Cho and Hee-Jong Lim. These partnerships enhance the research environment and contribute to the successful development of new therapeutic strategies.

Conclusion

Sae-Bom Yoon's contributions to the field of pharmaceutical sciences highlight the importance of innovation in addressing complex health issues. His patent for a tricyclic compound as an IRAK4 inhibitor represents a significant step forward in the treatment of autoimmune diseases and tumors.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…